SNX281 is a selective STING agonist, with IC50 values of 4.1, 4.5, 10.7, and 3.7 µM against human, mouse, rat, and monkey STING, respectively. SNX281 undergoes homodimerization at the STING binding site, triggering a conformational shift of STING from an inactive open state to an active closed state, thereby driving downstream STING-dependent signaling pathways. SNX281 induces type I interferons, IFN-beta, TNF-alpha, IL-6, cytokine release, T cell responses, and long-lasting immune memory. SNX281 exhibits anti-tumor activity and is applicable to research related to colorectal cancer, melanoma, advanced solid tumors, lymphoma, and ovarian cancer[1].
Molekulargewicht:
389.90
Reinheit:
99.08
CAS Nummer:
[2332803-84-4]
Formel:
C20H20ClNO3S
Target-Kategorie:
IFNAR,Interleukin Related,STING
Anwendungsbeschreibung:
MCE Product type: Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
